
Vanessa Roldan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4763098/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, 2018, 39, 1330-1393.	1.0	1,576
2	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	0.7	951
3	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	0.7	494
4	Statins and Postoperative Risk of Atrial Fibrillation Following Coronary Artery Bypass Grafting. American Journal of Cardiology, 2006, 97, 55-60.	0.7	204
5	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace, 2018, 20, 1231-1242.	0.7	194
6	Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thrombosis and Haemostasis, 2013, 110, 1189-1198.	1.8	182
7	Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a "Real-World―Population With Atrial Fibrillation Receiving Anticoagulant Therapy. Chest, 2013, 143, 179-184.	0.4	176
8	The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 62, 2199-2204.	1.2	171
9	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace, 2015, 17, 1197-1214.	0.7	160
10	Soluble E-selectin in cardiovascular disease and its risk factors. Thrombosis and Haemostasis, 2003, 90, 1007-1020.	1.8	148
11	Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 312-318.	2.1	123
12	Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients. Journal of the American College of Cardiology, 2011, 57, 2496-2504.	1.2	121
13	Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. European Heart Journal, 2003, 24, 1373-1380.	1.0	118
14	SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation. American Journal of Medicine, 2014, 127, 1083-1088.	0.6	112
15	Renal Impairment in a "Real-Life―Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding). American Journal of Cardiology, 2013, 111, 1159-1164.	0.7	110
16	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood, 2007, 109, 4258-4263.	0.6	104
17	Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. Thrombosis and Haemostasis, 2013, 109, 956-960.	1.8	102
18	High sensitivity cardiac troponin T and interleukinâ€6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. Journal of Thrombosis and Haemostasis, 2012, 10, 1500-1507	1.9	97

#	Article	IF	CITATIONS
19	Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?. Stroke, 2003, 34, 1181-1186.	1.0	93
20	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Journal of the American College of Cardiology, 2009, 54, 1041-1057.	1.2	92
21	A multimarker risk stratification approach to nonâ€ST elevation acute coronary syndrome: implications of troponin T, CRP, NT proâ€BNP and fibrin Dâ€dimer levels. Journal of Internal Medicine, 2007, 262, 651-658.	2.7	87
22	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. American Heart Journal, 2008, 156, 85-91.	1.2	80
23	Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thrombosis Research, 2009, 124, 174-177.	0.8	78
24	Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. European Heart Journal, 2008, 30, 139-151.	1.0	74
25	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thrombosis and Haemostasis, 2017, 117, 1448-1454.	1.8	74
26	Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood, 2009, 113, 4977-4979.	0.6	73
27	Premature myocardial infarction: Clinical profile and angiographic findings. International Journal of Cardiology, 2008, 126, 127-129.	0.8	67
28	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 892-902.	1.1	66
29	Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?. Circulation: Cardiovascular Interventions, 2012, 5, 459-466.	1.4	60
30	Hypofibrinolysis in atrial fibrillation. American Heart Journal, 1998, 136, 956-960.	1.2	59
31	A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood, 2006, 108, 177-183.	0.6	58
32	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. Thrombosis and Haemostasis, 2019, 119, 1901-1919.	1.8	57
33	Premature coronary artery disease in young (age < 45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers. International Journal of Cardiology, 2009, 136, 222-225.	0.8	56
34	Long-term bleeding risk prediction in â€~real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. Thrombosis and Haemostasis, 2017, 117, 1848-1858.	1.8	56
35	The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective â€ ⁻ Real-world' Inception Cohort Study. American Journal of Medicine, 2015, 128, 1237-1243.	0.6	51
36	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. Thrombosis and Haemostasis, 2017, 117, 2261-2266.	1.8	51

#	Article	IF	CITATIONS
37	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. Stroke, 2019, 50, 1372-1379.	1.0	48
38	Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. European Heart Journal, 2008, 30, 932-939.	1.0	44
39	Longâ€Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABCâ€Stroke and CHA ₂ DS ₂ â€VASc Scores. Journal of the American Heart Association, 2017, 6, .	1.6	42
40	Valor predictivo de la escala CHA2DS2-VASc en pacientes con fibrilación auricular de alto riesgo embólico en tratamiento anticoagulante. Revista Espanola De Cardiologia, 2012, 65, 627-633.	0.6	41
41	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. Thrombosis and Haemostasis, 2020, 120, 1200-1207.	1.8	41
42	Usefulness of N-Terminal Pro–B-Type Natriuretic Peptide Levels for Stroke Risk Prediction in Anticoagulated Patients With Atrial Fibrillation. Stroke, 2014, 45, 696-701.	1.0	39
43	Quality of oral anticoagulation with vitamin K antagonists in â€~real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace, 2018, 20, 1435-1441.	0.7	39
44	The association of the Â1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica, 2007, 92, 513-518.	1.7	38
45	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed), 2020, 73, 749-757.	0.4	38
46	Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. European Heart Journal, 2007, 28, 3006-3011.	1.0	37
47	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thrombosis and Haemostasis, 2009, 101, 483-486.	1.8	37
48	Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. Thrombosis Journal, 2015, 13, 22.	0.9	37
49	Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2004, 37, 699-704.	0.9	36
50	miR-133a Regulates Vitamin K 2,3-Epoxide Reductase Complex Subunit 1 (VKORC1), a Key Protein in the Vitamin K Cycle. Molecular Medicine, 2012, 18, 1466-1472.	1.9	36
51	Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 781-788.	1.8	36
52	Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thrombosis Research, 2005, 116, 321-325.	0.8	35
53	Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. Revista Espanola De Cardiologia (English) Tj	етоq11 с).78 ³ 514 rg8

54 Fibrinolytic function and atrial fibrillation. Thrombosis Research, 2003, 109, 233-240.

0.8 34

#	Article	IF	CITATIONS
55	Endothelial protein C receptor polymorphisms and risk of myocardial infarction. Haematologica, 2008, 93, 1358-1363.	1.7	34
56	Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications. Journal of Cardiac Failure, 2008, 14, 414-419.	0.7	33
57	Are there ethnic differences in the circadian variation in onset of acute myocardial infarction?. International Journal of Cardiology, 2005, 100, 151-154.	0.8	31
58	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. Scientific Reports, 2017, 7, 41565.	1.6	31
59	Creating a genotype-based dosing algorithm for acenocoumarol steady dose. Thrombosis and Haemostasis, 2013, 109, 146-153.	1.8	30
60	Association of the Thrombomodulin Gene c.1418C>T Polymorphism With Thrombomodulin Levels and With Venous Thrombosis Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1435-1440.	1.1	30
61	En el camino de un mejor uso de los anticoagulantes en la fibrilación auricular no valvular. Propuesta de modificación del posicionamiento terapéutico UT/V4/23122013. Revista Espanola De Cardiologia, 2016, 69, 551-553.	0.6	28
62	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World―vs Clinical Trials. Mayo Clinic Proceedings, 2018, 93, 1065-1073.	1.4	28
63	Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. Thrombosis and Haemostasis, 2005, 94, 1294-1299.	1.8	27
64	A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 2005, 45, 25-29.	1.2	27
65	Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. American Journal of Cardiology, 2005, 95, 881-882.	0.7	26
66	Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. American Journal of Cardiology, 2003, 91, 1242-1245.	0.7	25
67	Prognostic Value of Mean Platelet Volume in Patients With Non-ST-Elevation Acute Coronary Syndrome. Angiology, 2012, 63, 241-244.	0.8	25
68	Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease. Annals of Medicine, 2013, 45, 274-290.	1.5	25
69	Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation. American Journal of Cardiology, 1999, 84, 862-864.	0.7	24
70	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opinion on Drug Safety, 2017, 16, 1051-1062.	1.0	24
71	Effect of Statins on Preventing Recurrence of Atrial Fibrillation After Electrical Cardioversion. American Journal of Cardiology, 2006, 98, 1299-1300.	0.7	23
72	Novel Oral Anticoagulants in Cardiovascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 34-44.	1.0	23

#	Article	IF	CITATIONS
73	Effect of <i><scp>CYP</scp>4F2</i> , <i><scp>VKORC</scp>1</i> , and <i><scp>CYP</scp>2C9</i> in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	2.3	23
74	Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. Haematologica, 2010, 95, 863-866.	1.7	22
75	Oral anticoagulation in chronic kidney disease: A huge challenge. Thrombosis and Haemostasis, 2012, 108, 3-5.	1.8	22
76	Enhancing the â€~real world' prediction of cardiovascular events and major bleeding with the CHA ₂ DS ₂ -VASc and HAS-BLED scores using multiple biomarkers. Annals of Medicine, 2018, 50, 26-34.	1.5	22
77	Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. European Journal of Clinical Investigation, 2012, 42, 1302-1308.	1.7	21
78	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. Circulation Journal, 2016, 80, 2102-2108.	0.7	21
79	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clinical Therapeutics, 2018, 40, 114-122.	1.1	21
80	The prognostic value of biomarkers after a premature myocardial infarction. International Journal of Cardiology, 2010, 143, 249-254.	0.8	20
81	The prognostic role of the adiponectin levels in atrial fibrillation. European Journal of Clinical Investigation, 2013, 43, 168-173.	1.7	20
82	Regulation of TFPIα expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. Scientific Reports, 2017, 7, 43500.	1.6	20
83	sST2 levels are associated with all ause mortality in anticoagulated patients with atrial fibrillation. European Journal of Clinical Investigation, 2015, 45, 899-905.	1.7	19
84	Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. Journal of Atherosclerosis and Thrombosis, 2015, 22, 610-617.	0.9	19
85	The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thrombosis and Haemostasis, 2015, 113, 671-673.	1.8	19
86	MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha. PLoS ONE, 2016, 11, e0154751.	1.1	19
87	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 2176-2181.	0.7	19
88	Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. American Heart Journal, 2004, 148, 602-605.	1.2	18
89	GDF-15 and risk stratification in atrial fibrillation. Nature Reviews Cardiology, 2015, 12, 8-9.	6.1	18
90	The SAMe-TT2R2score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2016, 14, 177-187.	0.6	18

#	Article	IF	CITATIONS
91	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in â€real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. International Journal of Cardiology, 2018, 254, 125-131.	0.8	18
92	Comparison of Estimated Glomerular Filtration Rate Equations for Dosing New Oral Anticoagulants in Patients With Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 497-504.	0.4	17
93	Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry. Thrombosis and Haemostasis, 2018, 118, 279-287.	1.8	17
94	Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica, 2005, 90, 421-3.	1.7	17
95	Clinical characteristics of patients with factor V Leiden or prothrombin G20210A and a first episode of venous thromboembolism. Findings from the RIETE Registry. Thrombosis Research, 2010, 126, 283-286.	0.8	16
96	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Scientific Reports, 2017, 7, 12066.	1.6	16
97	miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis. PLoS ONE, 2018, 13, e0198932.	1.1	16
98	Relationship between multimorbidity and outcomes in atrial fibrillation. Experimental Gerontology, 2021, 153, 111482.	1.2	16
99	Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements. PLoS ONE, 2013, 8, e64469.	1.1	16
100	Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Thrombosis and Haemostasis, 2008, 100, 754-755.	1.8	15
101	An Evaluation of the CHADS 2 Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization. Chest, 2011, 139, 1402-1409.	0.4	15
102	Implications of Pharmacogenetics for Oral Anticoagulants Metabolism. Current Drug Metabolism, 2009, 10, 632-642.	0.7	15
103	Factor VII –323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk. Annals of Medicine, 2008, 40, 553-559.	1.5	14
104	Predictive Value of the CHA2DS2-VASc Score in Atrial Fibrillation Patients at High Risk for Stroke Despite Oral Anticoagulation. Revista Espanola De Cardiologia (English Ed), 2012, 65, 627-633.	0.4	14
105	Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting. Age and Ageing, 2013, 42, 70-75.	0.7	14
106	Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. Journal of General Internal Medicine, 2018, 33, 847-854.	1.3	14
107	Effect of Factor XIII VAL34LEU Polymorphism on Thrombolytic Therapy in Premature Myocardial Infarction. Thrombosis and Haemostasis, 2002, 88, 354-355.	1.8	13
108	Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. International Journal of Cardiology, 2009, 132, 227-232.	0.8	13

#	Article	IF	CITATIONS
109	A nurseâ€led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. International Journal of Clinical Practice, 2020, 74, e13634.	0.8	13
110	Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction. International Journal of Cardiology, 2001, 78, 115-119.	0.8	12
111	CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. Annals of Medicine, 2010, 42, 439-446.	1.5	12
112	β-Trace Protein and Prognosis in Patients With Atrial Fibrillation Receiving Anticoagulation Treatment. Chest, 2013, 144, 1564-1570.	0.4	12
113	Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency. Thrombosis Research, 2018, 163, 64-70.	0.8	12
114	Increasing therapyâ€related myeloid neoplasms in multiple myeloma. European Journal of Clinical Investigation, 2018, 49, e13050.	1.7	12
115	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World―in Patients With Atrial Fibrillation. American Journal of Cardiology, 2018, 122, 785-792.	0.7	12
116	ALG12 DG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant. Molecular Genetics & Genomic Medicine, 2020, 8, e1304.	0.6	12
117	Common Carotid Artery Intima-Media Thickness and Intracranial Pulsatility Index in Non-ST-Elevation Acute Coronary Syndromes. Cerebrovascular Diseases, 2007, 24, 338-342.	0.8	11
118	Influence of the F12-4 C>T polymorphism on hemostatic tests. Blood Coagulation and Fibrinolysis, 2010, 21, 632-639.	0.5	11
119	The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are biomarkers really ready for real world usage?. Heart, 2010, 96, 227-228.	1.2	11
120	Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: A pilot study. Thrombosis Research, 2011, 128, 391-394.	0.8	11
121	Comparative Determination and Monitoring of Biomarkers of Necrosis and Myocardial Remodeling between Radiofrequency Ablation and Cryoablation. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 31-36.	0.5	11
122	Comentarios a la guÃa ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular. Revista Espanola De Cardiologia, 2017, 70, 2-8.	0.6	11
123	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 3645.	1.0	11
124	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace, 2022, 24, 1844-1871.	0.7	11
125	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Annals of Medicine, 2010, 42, 562-575.	1.5	10
126	Genotype-guided therapy improves initial acenocoumarol dosing. Thrombosis and Haemostasis, 2016, 115, 117-125.	1.8	10

#	Article	IF	CITATIONS
127	On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013. Revista Espanola De Cardiologia (English Ed), 2016, 69, 551-553.	0.4	10
128	Repercusiones en la posologÃa de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardiaca aguda reciente. Revista Espanola De Cardiologia, 2016, 69, 134-140.	0.6	9
129	Factor XII in PMM2-CDG patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway. Orphanet Journal of Rare Diseases, 2020, 15, 280.	1.2	9
130	Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. Journal of Clinical Medicine, 2021, 10, 715.	1.0	9
131	Effect ofVKORC1, CYP2C9andCYP4F2genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics, 2014, 15, 987-996.	0.6	8
132	Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA 2 DS 2 -VASc and HAS-BLED. American Heart Journal, 2018, 197, 27-34.	1.2	8
133	Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. Thrombosis and Haemostasis, 2019, 119, 1409-1418.	1.8	8
134	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. Mayo Clinic Proceedings, 2020, 95, 2360-2369.	1.4	8
135	Number needed to treat for net effect of anticoagulation in atrial fibrillation: Realâ€world <i>vs</i> . clinicalâ€ŧrial evidence. British Journal of Clinical Pharmacology, 2022, 88, 282-289.	1.1	8
136	TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction. Thrombosis and Haemostasis, 2008, 100, 1211-1213.	1.8	6
137	Effects of atorvastatin 80Âmg daily on indices of matrix remodelling in â€~high-risk' patients with ischemic heart disease. International Journal of Cardiology, 2010, 139, 95-97.	0.8	6
138	The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. International Journal of Cardiology, 2016, 217, 42-48.	0.8	6
139	Influence of smoking habit on cardiac functional capacity and diastolic function in healthy people. International Journal of Cardiology, 2005, 98, 517-518.	0.8	5
140	Is an advanced age an additive risk factor to the prothrombotic or hypercoagulable state in atrial fibrillation?. International Journal of Cardiology, 2006, 110, 265-266.	0.8	5
141	Pro: "Antidote for new anticoagulants―– Specific target of inhibition requires a specific target for neutralisation. Thrombosis and Haemostasis, 2012, 108, 621-622.	1.8	5
142	Conventional and New Oral Anticoagulants in the Treatment of Chest Disease and Its Complications. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 413-421.	2.5	5
143	Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. Circulation Journal, 2016, 80, 605-612.	0.7	5
144	Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery. Europace, 2016, 18, 1328-1334.	0.7	5

#	Article	IF	CITATIONS
145	Comments on the 2016 ESC Guidelines for the Management of Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2017, 70, 2-8.	0.4	5
146	Applicability of the modified CHA 2 DS 2 -VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. European Journal of Internal Medicine, 2017, 38, e21-e22.	1.0	5
147	Predicting bleeding risk after coronary surgery: Let's focus on modifiable risk factors and simple, practical decision making. Thrombosis and Haemostasis, 2017, 117, 647-649.	1.8	5
148	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. European Journal of Clinical Investigation, 2018, 48, e12929.	1.7	5
149	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Current Medicinal Chemistry Cardiovascular and Hematological Agents, 2005, 3, 357-364.	1.7	4
150	Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. Revista Espanola De Cardiologia (English Ed), 2005, 58, 934-940.	0.4	4
151	Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers?. Journal of Thrombosis and Thrombolysis, 2006, 21, 163-166.	1.0	4
152	γ-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. Thrombosis Research, 2008, 122, 429-431.	0.8	4
153	Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance. Annals of Medicine, 2009, 41, 547-558.	1.5	4
154	Hypouricemic effect of statins: Another pleiotropic benefit?. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 1358-1359.	0.4	4
155	Assessment of bleeding risk in acute ill medical patients. An essential part of venous thromboembolism prevention. Thrombosis and Haemostasis, 2016, 116, 403-404.	1.8	4
156	Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Revista Espanola De Cardiologia (English Ed), 2016, 69, 134-140.	0.4	4
157	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. International Journal of Clinical Practice, 2018, 72, e13069.	0.8	4
158	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. Circulation Journal, 2018, 82, 1286-1292.	0.7	4
159	Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. Journal of Clinical Medicine, 2021, 10, 3357.	1.0	4
160	Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. Cardiology Journal, 2018, 25, 151-154.	0.5	4
161	Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. Frontiers in Cardiovascular Medicine, 2021, 8, 787235.	1.1	4
162	Relation of the â€~Atrial Fibrillation Better Care (ABC) Pathway' to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. Journal of Personalized Medicine, 2022, 12, 487.	1.1	4

#	Article	IF	CITATIONS
163	Anticoagulant Therapy Modifies Fibrinolytic Dysfunction in Chronic Atrial Fibrillation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 219-224.	0.5	3
164	Do protein Z levels influence the prothrombotic state in atrial fibrillation?. Thrombosis Research, 2002, 106, 269-270.	0.8	3
165	Genetic Polymorphisms and Thromoembolic Risk in Atrial Fibrillation. Journal of Thrombosis and Thrombolysis, 2004, 18, 151-152.	1.0	3
166	Antiplatelet versus anticoagulant therapies in advanced age: An unfinished task. International Journal of Cardiology, 2006, 110, 271-272.	0.8	3
167	Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders. Annals of Hematology, 2010, 89, 1147-1154.	0.8	3
168	Strategies for prediction and early detection of atrial fibrillation: present and future. Europace, 2016, 19, euw131.	0.7	3
169	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. BMJ Open, 2019, 9, e033712.	0.8	3
170	Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 183-188.	0.2	3
171	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. Expert Opinion on Pharmacotherapy, 2020, 21, 1867-1881.	0.9	3
172	Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA study. European Journal of Internal Medicine, 2020, 78, 63-68.	1.0	3
173	Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody. Thrombosis and Haemostasis, 2008, 100, 754-5.	1.8	3
174	Soluble E-selectin, interleukin-6 and tissue factor in two cases of meningococcal septicaemia. Blood Coagulation and Fibrinolysis, 2004, 15, 179-182.	0.5	2
175	Synergism between factor XII –4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. Thrombosis and Haemostasis, 2010, 104, 650-652.	1.8	2
176	The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort. Journal of General Internal Medicine, 2023, 38, 315-323.	1.3	2
177	Is plasminogen activator inhibitor-1 (PAI-1) a surrogate marker of vascular damage?. Thrombosis Research, 2011, 128, 601-602.	0.8	1
178	Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?. Expert Opinion on Pharmacotherapy, 2012, 13, 1087-1090.	0.9	1
179	Common Questions in Anticoagulation Management in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2014, 6, 79-86.	0.7	1
180	Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients. Biological Research for Nursing, 2017, 19, 198-205.	1.0	1

#	Article	IF	CITATIONS
181	Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis. Thrombosis and Haemostasis, 2018, 118, 806-807.	1.8	1
182	Oral anticoagulation and comorbidities; too many details for clinical practice?. International Journal of Cardiology, 2018, 264, 93-94.	0.8	1
183	Factor XI, much more than an innocent observer. Journal of Thrombosis and Haemostasis, 2020, 18, 3172-3173.	1.9	1
184	Outcomes in VKAâ€ŧreated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs â€~realâ€world'. International Journal of Clinical Practice, 2021, 75, e13888.	0.8	1
185	Anticoagulant therapy in patients with congenital FXI deficiency. Blood Advances, 2021, 5, 4083-4086.	2.5	1
186	New Role of Biomarkers in Atrial Fibrillation. , 2015, , 1-33.		1
187	Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients. European Journal of Internal Medicine, 2022, 98, 122-124.	1.0	1
188	Diurnal variation of international normalised ratio in patients under oral anticoagulation. Thrombosis Research, 2002, 108, 355.	0.8	0
189	Prothrombin fragment F1+2 and von Willebrand factor levels and left ventricular systolic function. Peripheral versus intracardiac blood samples. International Journal of Cardiology, 2002, 83, 289-290.	0.8	0
190	¿Podemos esperar de los polimorfismos las respuestas a nuestras dudas?. Revista Espanola De Cardiologia, 2004, 57, 1129.	0.6	0
191	Can We Expect Polymorphisms to Answer our Questions?. Revista Espanola De Cardiologia (English Ed) Tj ETQq1	10.7843 0.4	14 rgBT /Ove
192	Matrix metalloproteinases in atrial fibrillation. Journal of the American College of Cardiology, 2004, 43, 152.	1.2	0
193	Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated. Future Cardiology, 2006, 2, 197-203.	0.5	0
194	Letter by Roldaln et al Regarding Article, "Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass― Circulation, 2008, 117, e169; author reply e170.	1.6	0
195	Edoxaban in Japanese Patients With Nonvalvular Atrial Fibrillation. Circulation Journal, 2012, 76, 1826-1827.	0.7	0
196	C0235 Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency. Thrombosis Research, 2012, 130, S110-S111.	0.8	0
197	New Role of Biomarkers in Atrial Fibrillation. , 2016, , 507-539.		0
198	Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants. Revista Espanola De Cardiologia (English Ed), 2017, 70, 132-133.	0.4	0

#	Article	IF	CITATIONS
199	Angiogénesis y estatinas, ¿a mayor dosis, mayor beneficio?. Revista Espanola De Cardiologia, 2003, 56, 631-631.	0.6	0
200	Riesgo embólico, riesgo isquémico y riesgo hemorrágico. Revista Espanola De Cardiologia Suplementos, 2019, 18, 3-8.	0.2	0
201	Influence of the matrix type over the concentration of GDF-15. Journal of Investigative Medicine, 2020, 68, 1402-1404.	0.7	0
202	Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study. Medicina ClÂnica, 2022, , .	0.3	0
203	Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial. Journal of Thrombosis and Thrombolysis, 2022, , 1.	1.0	0
204	Diagnostic and therapeutic potential of miRNAs in cardiovascular disease: a clinical reality?. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.4	0